Volume 2.39 | Oct 14

Mammary Cell News 2.39 October 14, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Fox Chase Researchers Uncover Achilles’ Heel in Aggressive Breast Tumors  ShareThis
In an unexpected twist, researchers find that the loss of a single protein, Nedd9, initially slows cancer formation but then makes the tumors that do arise more aggressive. The good news, though, is that the lack of Nedd9 also makes the aggressive tumors more sensitive to a class of drugs that are already used in the clinic. [Press release from the Fox Chase Cancer Center discussing online prepublication in Cancer Research]

ON83_EpiCultVideo_645x110



SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at [email protected]



SCIENCE NEWS

Breast Density Linked to Increased Risk of Subsequent Breast Cancer
Researchers have found that patients with a very early form of breast cancer (ductal carcinoma in situ) who have higher mammographic density may be at increased risk for subsequent breast cancer, especially in the breast opposite to the one with the initial cancer. [Press release from the American Association for Cancer Research (AACR) discussing online prepublication in Cancer Epidemiology, Biomarkers & Prevention]

Creighton Study Offers Hope for Women with ER-Negative Breast Cancer
Women who have estrogen receptor-negative breast cancer may have more drug-treatment options than previously thought, a study suggests. [Press release from Creighton University discussing online prepublication in Oncogene]

Adding Cetuximab to Chemotherapy Doubles Response Rate in Hard-to-Treat Breast Cancer
European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer. [Press release from the European Society for Medical Oncology (ESMO) discussing data presented at the 35th ESMO Congress in Milan]

Iniparib Extends Overall Survival in Metastatic Triple-Negative Breast Cancer: Final Phase II Results
Women with an aggressive subtype of metastatic breast cancer appear to live an average of almost five months longer when treated with iniparib plus chemotherapy, compared to chemotherapy alone, the results of a randomized Phase II trial show. [Press release from the European Society for Medical Oncology (ESMO) discussing data presented at the 35th ESMO Congress in Milan]

EpiCultBMouse_645x110_v01



LABORATORY RESEARCH

Filamin A Regulates Focal Adhesion Disassembly and Suppresses Breast Cancer Cell Migration and Invasion
In this study, researchers report that actin cross-linking protein filamin A (FLNa) suppresses invasion of breast cancer cells and regulates focal adhesion turnover. [J Exp Med]

Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics
Researchers investigated whether prolonged continuous selection of cells for drug resistance enriches cultures for cancer stem-like cells. [J Natl Cancer Inst]

Methionine Sulfoxide Reductase A Down-Regulation in Human Breast Cancer Cells Results in a More Aggressive Phenotype
In the present study, researchers show that methionine sulfoxide reductase A, which is known to protect proteins from oxidation and which acts as a reactive oxygen species scavenger, is down-regulated in a number of breast cancers. [Proc Natl Acad Sci USA]

Enhanced Genetic Instability and Dasatinib Sensitivity in Mammary Tumor Cells Lacking NEDD9
The studies identify NEDD9 as a complex modulator of different aspects of mammary tumor growth. [Cancer Res]

A Positive Feedback Loop of ER-Alpha36/EGFR Promotes Malignant Growth of ER-Negative Breast Cancer Cells
In this study, researchers found that ER-Alpha36 was highly expressed in 10/12 cases of triple-negative breast cancer. [Oncogene]

RARalpha1 Control of Mammary Gland Ductal Morphogenesis and Wnt1-Tumorigenesis
Retinoic acid signaling pathways are disabled in human breast cancer suggesting a controlling role in normal mammary growth that might be lost in tumorigenesis. Researchers tested a single receptor isotype, RARalpha1, for its role in mouse mammary gland morphogenesis and MMTV-wnt1-induced oncogenesis. [Breast Cancer Res]

CLINICAL RESEARCH

Effectiveness of Tocotrienol-Rich Fraction Combined with Tamoxifen in the Management of Women with Early Breast Cancer: A Pilot Clinical Trial
Researchers conducted a double-blinded, placebo-controlled pilot trial to test the effectiveness of adjuvant tocotrienol therapy in combination with tamoxifen for five years in women with early breast cancer. [Breast Cancer Res]

Stability of Estrogen Receptor (ER) Status in Breast Carcinoma
The purposes of this study were to address a persistent controversy as to whether the ER status of a primary tumor remains stable during progression to metastasis and to evaluate the influence of disease course and prior systemic therapy on ER status. [Cancer]

INDUSTRY NEWS

Roche Reports Positive Data for Avastin in Ovarian Cancer and T-DM1 in Breast Cancer
Roche announced that new data released at the 35th Congress of the European Society of Medical Oncology (ESMO) congress continue to support Roche’s development programs for Avastin in ovarian cancer and T-DM1 in HER2-positive breast cancer. [F. Hoffmann-La Roche Ltd. Press Release]

Genomic Health Announces Analysis From First European Clinical Decision Making Study of Oncotype DX(R) Breast Cancer Test Among Spanish Physicians
Genomic Health, Inc. announced positive results from a prospective, multi-center, study that showed the Oncotype DX(R) Recurrence Score(R) result had a significant impact on treatment decisions for early-stage breast cancer patients in Spain. [Genomic Health, Inc. Press Release]

ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Data for Lorvotuzumab Mertansine at ESMO Annual Meeting
ImmunoGen, Inc. announced the presentation of encouraging clinical data for the Company’s lorvotuzumab mertansine (IMGN901) targeted anticancer compound at the 35th European Society for Medical Oncology (ESMO) Conference. [ImmunoGen, Inc. Press Release]

STEMSOFT Connect – A Simplified Solution to a Complex Problem
STEMSOFT Software Inc. is pleased to announce the release of their new standard interfaces, STEMSOFT Connect(TM). [STEMSOFT Software Inc. Press Release]

Diamonds Donate $3 Million to Fight Breast Cancer
Breast-cancer detection in B.C. will take a giant leap forward, thanks to a $3 million donation from the Gordon and Leslie Diamond family to the Canadian Breast Cancer Foundation and B.C. Women’s Hospital. [The Vancouver Sun]



POLICY NEWS

NIH Announces New Program to Accelerate Research Independence
The National Institutes of Health intends to invest approximately $60 million over the next five years in the NIH Director’s Early Independence Award program to help junior investigators leapfrog over traditional post-doctoral training and move into independent academic positions at U.S. institutions, directly upon completion of their graduate research degrees. [National Institutes of Health, United States]

NIH Launches Genotype-Tissue Expression Project
The National Institutes of Health (NIH) announced awards to support an initiative to understand how genetic variation may control gene activity and its relationship to disease. Launched as a pilot phase, the Genotype-Tissue Expression (GTEx) project will create a resource researchers can use to study inherited susceptibility to illness and will establish a tissue bank for future biological studies. [National Institutes of Health, United States]

FDA’s $25 Million Pitch for Improving Drug Regulation
The U.S. Food and Drug Administration (FDA) is pressing for a big funding boost for “regulatory science”- research that can help it evaluate new treatments better and faster. [Food and Drug Administration, United States]

FDA to Push for More Investment in Science
Health regulators plan to spend millions of dollars to step up their scientific prowess in a move that officials say will help quickly get new treatments to patients and protect the public against possible health threats. [Food and Drug Administration, United States]

FDA Issues Regulatory Science Report
The U.S. Food and Drug Administration unveiled a report outlining the agency’s plans to advance regulatory science through its Regulatory Science Initiative. [Food and Drug Administration, United States]

Plan to Develop a Genetic Testing Registry at the National Institutes of Health; Public Meeting; Request for Comments (FR Doc. 2010-25411) [National Institutes of Health, United States]

Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-25171) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-25180) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-25185) [National Institutes of Health, United States]

National Center for Research Resources; Notice of Closed Meeting (FR Doc. 2010-25176) [National Institutes of Health, United States]

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting (FR Doc. 2010-25172) [National Institutes of Health, United States]



EVENTS (Listed by Date)

International Symposium on Breast Cancer Prevention: Nutrition, Communications and Public Policy
October 18-19, 2010
West Lafayette, United States

6th Modern Drug Discovery & Development Summit (M3D)
October 20-22, 2010
San Francisco, United States

16th World Congress of the Senologic International Society
October 20-22, 2010
Valencia, Spain

American Institute for Cancer Research (AICR) 2010 Annual Cancer Research Conference
October 21-22, 2010
Washington, DC, United States

MENA Oncology Conference
October 22-23, 2010
Cairo, Egypt

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

2nd Annual Stem Cells Asia and Regenerative Medicine Congress
October 26-28, 2010
Seoul, Korea

UAE Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

The 16th International Conference of the International Society of Differentiation: From Stem Cells to Organisms
November 15-18, 2010
Nara, Japan

22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

33rd Annual San Antonio Breast Cancer Symposium
December 8-12, 2010
San Antonio, United States

Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

28th Annual Miami Breast Cancer Conference
March 9-12, 2011
Miami, United States

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Clean Room Team Leader – Cellular Therapy (Cell Medica Limited)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us